Food and Drug Administration

Dermatologic and Ophthalmic Drugs Advisory Committee

September 10, 2003


The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Executive Summary, PhotoCure ASA (PDF)

Briefing Document Regarding Photodynamic Therapy With Methyl Aminolevulinate Cream for Treatment of Basal Cell Carcinoma, PhotoCure ASA (HTM) (PDF) (Word)

Briefing Document Regarding Methyl Aminolevulinate Hydrochloride Cream 168 mg/g (MAL), FDA (HTM) (PDF) (Word)